Verséa to distribute Celularity’s ophthalmic allograft products
Click Here to Manage Email Alerts
Key takeaways:
- Celularity and Verséa Ophthalmics have entered into a U.S. commercialization agreement.
- Verséa will distribute Biovance and Biovance 3L Ocular for ocular surface treatment and surgical support.
Verséa Ophthalmics will distribute Celularity’s Biovance and Biovance 3L Ocular products for ocular surface disease treatment and ocular surgical support under the terms of an exclusive U.S. commercialization agreement.
Biovance and Biovance 3L Ocular are single-layer and three-layer allografts, respectively, designed to be used as a biological membrane covering, according to a press release. In addition, Biovance 3L Ocular protects underlying tissue and preserves tissue plane boundaries.
Product applications include corneal and conjunctival-related injuries or defects, including corneal epithelial defects, pterygium repair and fornix reconstruction.
“We are excited to partner with Verséa Ophthalmics to distribute our Biovance and
Biovance 3L Ocular products in the U.S.,” Robert J. Hariri, MD, PhD, CEO, chairman and founder of Celularity, said in the release. “Verséa Ophthalmics has the channel expertise in eye care necessary to reach physicians and to provide patients in need access to our innovative biomaterial technology.”
Read more about
Click Here to Manage Email Alerts